On March 28, 2017, we issued a press release in which we reported results from EVOLVE and EXPAND, two Phase 3 clinical trials of tezacaftor in combination with ivacaftor.

A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Description of Document

99.1 Press Release, dated March 28, 2017.

About VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.

VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Recent Trading Information

VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) closed its last trading session down -1.13 at 89.67 with 1,561,363 shares trading hands.